MIMinae Isawa

Minae Isawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minae Isawa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study

    by Yukiko Ohno, Tohru Aomori, Tomohiro Nishiyama, Riri Kato, Reina Fujiki, Haruki Ishikawa, Keisuke Kiyomiya, Minae Isawa, Mayumi Mochizuki, Eiji Aramaki, et al.

    Background: Patients’ oral expressions serve as valuable sources of clinical information to improve pharmacotherapy. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. Objective: We aimed to develop a high-performance NLP system for extracting clinical information from patient narratives by examining the performance progression with a gradual increase in the amount of training data. Methods: We used subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018, to March 31, 2019, comprising 12,004 records from 6559 cases. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated a deep learning model (bidirectional encoder representations from transformers combined with a conditional random field [BERT-CRF]) through 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. Results: The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1200 to 12,004 records. The F1-score reached 0.78 with 3600 records and was largely similar thereafter. As performance improved, errors from incorrect extractions decreased significantly, which resulted in an increase in precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. Conclusions: We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.


  • Open Access

    Performance Improvement of the Natural Language Processing Tool to Extract Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records: Effects of an Increase in the Amount of Training Data (Preprint)

    by Yukiko Ohno, Tohru Aomori, Tomohiro Nishiyama, Riri Kato, Reina Fujiki, Haruki Ishikawa, Keisuke Kiyomiya, Minae Isawa, Mayumi Mochizuki, Eiji Aramaki, et al.

    BACKGROUND To improve pharmacotherapy, patients’ oral expressions serve as valuable sources of clinical information. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. OBJECTIVE To develop a high-performance NLP system for extracting clinical information from patient narratives, we examined the performance progression as the amount of training data was gradually increased. METHODS Subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018 to March 31, 2019, comprising 12,004 records from 6,559 cases, were used. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated deep learning models—bidirectional encoder representations from transformers combined with a conditional random field (BERT-CRF)—by 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. RESULTS The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1,200 to 12,004 records. The F1-score reached 0.78 with 3,600 records and largely saturated thereafter. As performance improved, errors from incorrect extractions decreased significantly, increasing precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1,200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. CONCLUSIONS We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3,600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.

  • Open Access

    Using the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis

    by Yukiko Ohno, Riri Kato, Haruki Ishikawa, Tomohiro Nishiyama, Minae Isawa, Mayumi Mochizuki, Eiji Aramaki, Tohru Aomori

    Background: Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. Objective: In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. Methods: MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. Results: The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. Conclusions: MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.


  • Open Access

    Using the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis (Preprint)

    by Yukiko Ohno, Riri Kato, Haruki Ishikawa, Tomohiro Nishiyama, Minae Isawa, Mayumi Mochizuki, Eiji Aramaki, Tohru Aomori

    BACKGROUND Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. OBJECTIVE In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. METHODS MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. RESULTS The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. CONCLUSIONS MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.

  • Prediction of Theophylline Clearance in CCl4-treated Rats Using in vivo CYP1A2 and CYP3A2 Contents Assessed with the PKCYP Test

    by Noriko Kose, Keiko Yamamoto, Yoshimichi Sai, Minae Isawa, Toshio Suwa, Emi Nakashima

    We previously established a method to predict the drug metabolism capacity of injured liver based on pharmacokinetic estimation of the amount of cytochrome P450 (CYP) in vivo (PKCYP test), by introducing the apparent liver-to-blood free concentration gradient in vivo (qg) as a parameter. Here we show that the amount of CYP3A2 in CCl(4)-treated rats can be estimated appropriately by applying the PKCYP test using midazolam (MDZ) as a probe, assuming that the qg value in control rats does not change. We applied the results to predict the clearance of theophylline as a model drug with a physiologically based pharmacokinetic model. Male Sprague-Dawley rats were pretreated with CCl4, and the amount of CYP (A-CYP(vivo)) was quantified by Western blotting. The qg value of MDZ was determined in control rats and used to estimate the amounts of CYP3A2 in CCl4-treated rats; the result agreed well with the observed values. The qg value of CYP3A2 estimated with MDZ as a probe was used together with our previously reported value for CYP1A2 (theophylline metabolism in the liver is known to be almost entirely mediated by CYP3A2 and CYP1A2) to predict the total body clearance (CL(tot)) of theophylline in CCl4-treated rats. The predicted CL(tot) was about one-third of the observed value, which was considered acceptable. The time-course of theophylline concentration in serum simulated with a physiologically-based pharmacokinetic model agreed well with the observed values. Thus, the PKCYP test using MDZ as a probe can be used to predict the amount of CYP3A2 and the CL(tot) of theophylline in CCl4-treated rats.